1
|
Dearnaley D, Hinder V, Hijab A, Horan G, Srihari N, Rich P, Houston G, Henry A, Gibbs S, Venkitaraman R, Cruickshank C, Hassan S, Mason M, Pedley I, Payne H, Brock S, Wade R, Robinson A, Din O, Lees K, Murray J, Parker C, Griffin C, Sohaib A, Hall E. OC-0105 PROMPTS RCT of screening MRI for spinal cord compression in prostate cancer (ISRCTN74112318). Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02481-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
2
|
Hunt A, Hanson I, Dunlop A, Barnes H, Bower L, Chick J, Cruickshank C, Hall E, Herbert T, Lawes R, McQuaid D, McNair H, Mitchell A, Mohajer J, Morgan T, Oelfke U, Smith G, Nill S, Huddart R, Hafeez S. Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer. Clin Transl Radiat Oncol 2020; 25:46-51. [PMID: 33015380 PMCID: PMC7522378 DOI: 10.1016/j.ctro.2020.09.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 09/03/2020] [Accepted: 09/06/2020] [Indexed: 12/15/2022] Open
Abstract
Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within 45 min. Intra-fraction bladder filling did not compromise target coverage. Patients reported acceptable tolerance of treatment.
Collapse
Affiliation(s)
- A. Hunt
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | - I. Hanson
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - A. Dunlop
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - H. Barnes
- The Royal Marsden NHS Foundation Trust, London, UK
| | - L. Bower
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | - J. Chick
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - C. Cruickshank
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
| | - E. Hall
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
| | - T. Herbert
- The Royal Marsden NHS Foundation Trust, London, UK
| | - R. Lawes
- The Royal Marsden NHS Foundation Trust, London, UK
| | - D. McQuaid
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - H. McNair
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | - A. Mitchell
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - J. Mohajer
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - T. Morgan
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | - U. Oelfke
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - G. Smith
- The Royal Marsden NHS Foundation Trust, London, UK
| | - S. Nill
- The Joint Department of Physics at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
| | - R. Huddart
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| | - S. Hafeez
- The Institute of Cancer Research, London, UK
- The Royal Marsden NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Dearnaley D, Syndikus I, Mossop H, Birtle A, Bloomfield D, Cruickshank C, Graham J, Hassan S, Khoo V, Logue J, Mayles H, Money-Kyrle J, Naismith O, Panades M, Patterson H, Scrase C, Staffurth J, Tremlett J, Griffin C, Hall E. 8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31932-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
4
|
Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, Elliott T, Thomson A, Burnett S, Cruickshank C, Carrington B, Waters R, Bahl A. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer 2013; 109:2554-9. [PMID: 24169355 PMCID: PMC3833214 DOI: 10.1038/bjc.2013.620] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2013] [Revised: 09/11/2013] [Accepted: 09/15/2013] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND Penis cancer is rare and clinical trial evidence on which to base treatment decisions is limited. Case reports suggest that the combination of docetaxel, cisplatin and 5-flurouracil (TPF) is highly active in this disease. METHODS Twenty-nine patients with locally advanced or metastatic squamous carcinoma of the penis were recruited into a single-arm phase II trial from nine UK centres. Up to three cycles of chemotherapy were received (docetaxel 75 mg m(-2) day 1, cisplatin 60 mg m(-2) day 1, 5-flurouracil 750 mg m(-2) per day days 1-5, repeated every 3 weeks). Primary outcome was objective response (assessed by RECIST). Fourteen or more responses in 26 evaluable patients were required to confirm a response rate of 60% or higher (Fleming-A'Hern design), warranting further evaluation. Secondary endpoints included toxicity and survival. RESULTS 10/26 evaluable patients (38.5%, 95% CI: 20.2-59.4) achieved an objective response. Two patients with locally advanced disease achieved radiological complete remission. 65.5% of patients experienced at least one grade 3/4 adverse event. CONCLUSION Docetaxel, cisplatin and 5FU did not reach the pre-determined threshold for further research and caused significant toxicity. Our results do not support the routine use of TPF. The observed complete responses support further investigation of combination chemotherapy in the neoadjuvant setting.
Collapse
Affiliation(s)
- S Nicholson
- Imperial College Healthcare NHS Trust, Department of Medical Oncology, Charing Cross Hospital, London W6 8RF, UK
| | - E Hall
- The Institute of Cancer Research, Clinical Trials & Statistics Unit, 123 Old Brompton Road, London SW7 3RP, UK
| | - S J Harland
- Department of Oncology, University College London Hospitals NHSFT, 250 Euston Road, London NW1 2PG, UK
| | - J D Chester
- Leeds Institute of Molecular Medicine, University of Leeds and St. James's Institute of Oncology, St James's University Hospital, Leeds LS9 7TF, UK
| | - L Pickering
- Department of Oncology, St. Georges Hospital, Blackshaw Road, Tooting, London SW17 0QT, UK
| | - J Barber
- Velindre Cancer Centre, Velindre Hospital, Velindre Road, Whitchurch, Cardiff CF14 2TL, UK
| | - T Elliott
- Department of Clinical Oncology, The Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
| | - A Thomson
- Department of Oncology, Royal Cornwall Hospital, London Road, Treliske, Truro TR1 3LJ, UK
| | - S Burnett
- The Institute of Cancer Research, Clinical Trials & Statistics Unit, 123 Old Brompton Road, London SW7 3RP, UK
| | - C Cruickshank
- The Institute of Cancer Research, Clinical Trials & Statistics Unit, 123 Old Brompton Road, London SW7 3RP, UK
| | - B Carrington
- Department of Diagnostic Radiotherapy, The Christie Hospital, Manchester, UK
| | - R Waters
- The Institute of Cancer Research, Clinical Trials & Statistics Unit, 123 Old Brompton Road, London SW7 3RP, UK
| | - A Bahl
- Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
| |
Collapse
|
5
|
Benson C, White J, Bono JD, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2006; 96:29-37. [PMID: 17179992 PMCID: PMC2360206 DOI: 10.1038/sj.bjc.6603509] [Citation(s) in RCA: 199] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range of human tumour xenografts. A phase I trial was performed with a 7-day b.i.d. p.o. schedule. Twenty-one patients (median age 62 years, range: 39-73 years) were treated with doses of 100, 200 and 800 b.i.d. Dose-limiting toxicities were seen at 800 mg b.i.d.; grade 3 fatigue, grade 3 skin rash, grade 3 hyponatraemia and grade 4 hypokalaemia. Other toxicities included reversible raised creatinine (grade 2), reversible grade 3 abnormal liver function and grade 2 emesis. An 800 mg portion was investigated further in 12 patients, three of whom had MAG3 renograms. One patient with a rapid increase in creatinine on day 3 had a reversible fall in renal perfusion, with full recovery by day 14, and no changes suggestive of renal tubular damage. Further dose escalation was precluded by hypokalaemia. Seliciclib reached peak plasma concentrations between 1 and 4 h and elimination half-life was 2-5 h. Inhibition of retinoblastoma protein phosphorylation was not demonstrated in peripheral blood mononuclear cells. No objective tumour responses were noted, but disease stabilisation was recorded in eight patients; this lasted for a total of six courses (18 weeks) in a patient with ovarian cancer.
Collapse
Affiliation(s)
- C Benson
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
- Section of Medicine, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
| | - J White
- Department of Medical Oncology and Beatson Oncology Centre, University of Glasgow, Glasgow, UK
| | - J De Bono
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
- Section of Medicine, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
| | - A O'Donnell
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
| | - F Raynaud
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
| | - C Cruickshank
- Cancer Research UK Drug Development Office, London, UK
| | | | - M Walton
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
| | - P Workman
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
| | - S Kaye
- Section of Medicine, The Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
| | - J Cassidy
- Department of Medical Oncology and Beatson Oncology Centre, University of Glasgow, Glasgow, UK
| | | | - I Judson
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, UK. E-mail:
| | - C Twelves
- Beatson Oncology Centre, Glasgow, UK
| |
Collapse
|
6
|
Lee C, Appleton K, Plumb J, Kaye S, Cruickshank C, Twelves C, Vasey P, Judson I, Brown R, Mackay H. A phase I trial of the DNA-hypomethylating agent 5-Aza-2'-Deoxycytidine in combination with carboplatin both given 4 weekly by intravenous injection in patients with advanced solid tumours. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- C. Lee
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - K. Appleton
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - J. Plumb
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - S. Kaye
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - C. Cruickshank
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - C. Twelves
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - P. Vasey
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - I. Judson
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - R. Brown
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| | - H. Mackay
- Institute of Cancer Research, Sutton, United Kingdom; Beatson Laboratories & Beatson Oncology Centre, Glasgow, United Kingdom; Royal Marsden Hospital, Sutton, United Kingdom; Drug Development Office, Cancer Research UK, London, United Kingdom
| |
Collapse
|
7
|
|
8
|
Cruickshank C. Clinical forum 3 - respiratory emergencies. Don't panic! Nurs Mirror 1982; 154:xiv-xv. [PMID: 6917266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|